C T Kouroukis
Overview
Explore the profile of C T Kouroukis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
103
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mian H, Brouwers M, Kouroukis C, Wildes T
J Frailty Aging
. 2019 Oct;
8(4):215-221.
PMID: 31637409
Multiple myeloma is a malignant plasma cell disease, which typically affects older patients, with a median age at diagnosis of 70 years. The challenge in treating older patients is to...
2.
Keech J, Beca J, Eisen A, Kennedy E, Kim J, Kouroukis C, et al.
Curr Oncol
. 2019 May;
26(2):e155-e161.
PMID: 31043821
Background: In Canada, requests for public reimbursement of cancer drugs are predominately initiated by pharmaceutical manufacturers. Clinician-led submissions provide a mechanism to initiate the drug funding process when industry does...
3.
Krzyzanowska M, Walker-Dilks C, Morris A, Gupta R, Halligan R, Kouroukis C, et al.
Cancer Treat Rev
. 2016 Nov;
51:35-45.
PMID: 27842279
Purpose: To define the optimal model of care for patients receiving outpatient chemotherapy who experience a fever. Fever is a common symptom in patients receiving chemotherapy, but the approach to...
4.
Kouroukis C, Varela N, Bredeson C, Kuruvilla J, Xenocostas A
Curr Oncol
. 2016 Aug;
23(4):e409-30.
PMID: 27536190
Background: High-dose chemotherapy with autologous stem-cell transplantation (asct) is an accepted part of standard therapy for patients with hematologic malignancies. Usually, stem-cell mobilization uses granulocyte colony-stimulating factor (g-csf); however, some...
5.
Kouroukis C, Crump M, MacDonald D, Larouche J, Stewart D, Johnston J, et al.
Curr Oncol
. 2015 Aug;
22(4):260-71.
PMID: 26300664
Background: Bendamustine is a bifunctional alkylating agent with unique properties that distinguish it from other agents in its class. Bendamustine is used as monotherapy or in combination with other agents...
6.
Bredeson C, Rumble R, Varela N, Kuruvilla J, Kouroukis C
Curr Oncol
. 2014 Apr;
21(2):e310-25.
PMID: 24764713
Question: Is there a benefit associated with the use of extracorporeal photopheresis (ecp) compared with other treatment options for patients who have received allogeneic stem-cell transplantation (sct) and are experiencing...
7.
Kouroukis C, Baldassarre F, Haynes A, Imrie K, Reece D, Cheung M
Clin Oncol (R Coll Radiol)
. 2013 Dec;
26(2):110-9.
PMID: 24321107
Aims: Bortezomib (Velcade™, PS-341), a first-in-class proteasome inhibitor, has been extensively studied either alone or in combination with other agents for the treatment of multiple myeloma. We created a provincial...
8.
Kouroukis C, Chia S, Verma S, Robson D, Desbiens C, Cripps C, et al.
Curr Oncol
. 2008 Mar;
15(1):9-23.
PMID: 18317581
Hematologic toxicities of cancer chemotherapy are common and often limit the ability to provide treatment in a timely and dose-intensive manner. These limitations may be of utmost importance in the...
9.
Mikhael J, Melosky B, Cripps C, Rayson D, Kouroukis C
Curr Oncol
. 2007 Oct;
14(5):209-17.
PMID: 17938704
Anemia is a common finding in cancer patients, most often as a result of chemotherapy. Management of anemia requires a comprehensive approach of appropriate diagnosis, exclusion of reversible causes, use...
10.
Belch A, Kouroukis C, Crump M, Sehn L, Gascoyne R, Klasa R, et al.
Ann Oncol
. 2006 Sep;
18(1):116-121.
PMID: 16971665
Background: We evaluated the activity and toxic effects of bortezomib in patients with mantle cell lymphoma. Patients And Methods: Thirty patients, including 29 eligible patients, were enrolled; 13 had received...